Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.58 |
| ▸ | KDR | P35968 | 5/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.56 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.56 |
| ▸ | FBP1 | P09467 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4232462 | 1.00 | EGFR (0.58) | EGFRKDREPHA2EPHB4FBP1 | |
| SCHEMBL4225836 | 0.92 | EGFR (0.58) | EGFRKDREPHA2EPHB4FBP1 | |
| SCHEMBL4219971 | 0.92 | EGFR (0.58) | EGFRKDREPHA2EPHB4FBP1 | |
| SCHEMBL4223752 | 0.91 | EGFR (0.70) | EGFRKDREPHB4FBP1ERBB2 | |
| SCHEMBL4222432 | 0.91 | EGFR (0.70) | EGFRKDREPHB4FBP1ERBB2 | |
| SCHEMBL4220580 | 0.87 | EGFR (0.57) | EGFRKDREPHA2EPHB4FBP1 | |
| SCHEMBL4226627 | 0.87 | EGFR (0.57) | EGFRKDREPHA2EPHB4FBP1 | |
| SCHEMBL6989473 | 0.84 | EGFR (0.58) | EGFRKDREPHA2EPHB4FBP1 | |
| SCHEMBL5225676 | 0.81 | EGFR (0.74) | EGFRKDREPHA2EPHB4FBP1 | |
| SCHEMBL1418194 | 0.80 | EGFR (0.70) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203683-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20060063752-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-23 | — | — | US | disclosed |
| EP-1163227-B1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-20020177601-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-11-28 | — | — | US | disclosed |
| EP-1163227-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM | Boehringer Ingelheim Pharma KG (DE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055141-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203683-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | REN, APC, PKD1 | EGFR 2063/4885KDR 3805/4885EPHA2 4344/4885 |
| US-20060063752-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | REN, APC, PKD1 | EGFR 2063/4885KDR 3805/4885EPHA2 4344/4885 |
| US-20020177601-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, BDKRB1 | EGFR 1367/4885KDR 4070/4885EPHA2 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.